Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects

Journal of Clinical Pharmacology

Volumn 46, Issue 11, 2006, Pages 1250-1258

  Yan, Jing He ^b   Bifano, Marc ^a,c   Olsen, Steven ^a   Smith, Robert A ^a   Zhang, Duxi ^a   Grasela, Dennis M ^a   LaCreta, Frank ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Entecavir; Healthy subject; Pharmacokinetics

Indexed keywords

ENTECAVIR; PLACEBO;

ACCIDENTAL INJURY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; ERYTHEMA; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; URINALYSIS; URINARY EXCRETION;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANINE; HUMANS; MALE; MIDDLE AGED;

EID: 33749844427     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006293304     Document Type: Article

References (30)

1. World Health Organization. Hepatitis B. Fact sheet WHO/204. Geneva, Switzerland: Word Health Organization, October 2000. Available at: http://www.who.int/mediacentre/factsheets/fs204/en. Accessed April 12, 2005.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.
3. Krogsgaard K, Bindslev N, Christensen E, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables: results based on individual patient data from 10 clinical controlled trials. J Hepatol. 1994;21:646-655.
4. Intron A (interferon alfa-2b recombinant) [package insert]. Kenilworth, NJ: Schering Corporation; 2002.
5. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000;32:828-834.
6. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19:1276-1282.
7. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000; 119:172-180.
8. Honkoop P, de Man R, Niesters H, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology. 2000;32:635-639.
9. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil (ADV) in HBeAg+ chronic hepatitis B patients: increasing serologic, virologic, and biochemical response over time. Hepatology. 2004;40(suppl):665A.
10. Borroto-Esoda K, Arterburn S, Snow A, et al. Final analysis of virological outcomes and resistance during 5-years of adefovir dipivoxil monotherapy in HBeAg-negative patients. J Hepatology. 2006;44(suppl 2):S179-S180.
11. Hepsera [package insert]. Foster City, Calif: Gilead Sciences; 2002.
12. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997;41:1444-1448.
13. Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis. 2001;184:1236-1245.
14. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010.
15. Lai CL, Shouval D, Lok A, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011-1020.
16. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J. Entecavir for treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B. Gastroenterology. 2006;130:2039-2049.
17. DeHertogh D, Colonno R, Olsen S, Thomas N, Kreter B. Rational dose identification of entecavir for chronic hepatitis B infection based on prospective evaluation of in vitro, animal model, clinical pharmacology, and human clinical trial data. Hepatology. 2002;36(4 pt 2):637A. Abstract 1878.
18. Gibaldi M. Non-compartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D, ed. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker, 1982:409-418.
19. Riegelman S. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm. 1980;8:509-534.
20. Fiske W, Olsen S, Yan J-H, Grasela D. Pharmacokinetic-pharmacodynamic modeling of entecavir: prediction of log decrease in hepatitis viral load. Hepatology. 2002;36(4 pt 2):631A. Abstract 1872.
21. Johnson MA, Moore KHP, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-66.
22. Adefovir dipivoxil [prescribing information]. Foster City, Calif: Gilead Sciences; 2005. Available at: http://www.gilead.com/wt/sec/adefovir. Accessed October 2005.
23. Baraclude [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2005.
24. Epivir-HBV [package insert]. Philadelphia, PA: Glaxo Smith-Kline; 2001.
25. Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother. 1999;43:190-193.
26. Chang C-N, Skalski V, Zhou J, Cheng YC. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem. 1992;267:22414-22420.
27. Greenberg ML, Allaudeen HS, Hershfield MS. Metabolism, toxicity, and anti-HIV activity of 2′-deoxy-3′-thiacytidine (BCH-189) in T and B cell lines. Ann N Y Acad Sci. 1990;616:517-518.
28. Cammack N, Rouse P, Marr P, et al. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol. 1992;43:2059-2064.
29. Chang T-T, Gish Robert G, Hadziyannis Stephanos J, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129:1198-1209.
30. Sherman M, Yurdaydin, C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130:2039-2049.